tradingkey.logo
tradingkey.logo
Suchen

Guardant Health Inc

GH
Zur Watchlist hinzufügen
153.740USD
+4.520+3.03%
Handelsschluss 06/29, 16:00ETKurse um 15 Minuten verzögert
20.22BMarktkapitalisierung
VerlustKGV TTM

mehr Informationen über Guardant Health Inc Unternehmen

Guardant Health, Inc. is a precision oncology company focused on guarding wellness and giving every person more time free from cancer. It provides critical insights into what drives disease through its advanced blood and tissue tests, real-world data, and artificial intelligence (AI) analytics. Guardant tests help improve outcomes across all stages of care, including screening to find cancer early, monitoring for recurrence in early-stage cancer, and helping doctors select the treatment for patients with advanced cancer. For patients with advanced-stage cancer, it has developed Guardant360 laboratory developed test (LDT), and Guardant360 CDx test, a comprehensive liquid biopsy test to provide tumor mutation profiling with solid tumors and to be used as a companion diagnostic in connection with non-small cell lung cancer (NSCLC), and breast cancer. It offers other tests, including Guardant360 Tissue test, Guardant Reveal blood test, Guardant360 Response blood test and others.

Guardant Health Inc Informationen

BörsenkürzelGH
Name des UnternehmensGuardant Health Inc
IPO-datumOct 04, 2018
CEOTalasaz (Amirali)
Anzahl der mitarbeiter1999
WertpapierartOrdinary Share
GeschäftsjahresendeOct 04
Addresse3100 Hanover Street
StadtPALO ALTO
BörseNASDAQ OMX - NASDAQ BASIC
LandUnited States of America
Postleitzahl94304
Telefon18556988887
Websitehttps://guardanthealth.com/
BörsenkürzelGH
IPO-datumOct 04, 2018
CEOTalasaz (Amirali)

Führungskräfte von Guardant Health Inc

Name
Name/Position
Position
Aktienbesitz
Veränderung
Dr. Helmy A. Eltoukhy, Ph.D.
Dr. Helmy A. Eltoukhy, Ph.D.
Chairperson of the Board, Co-Chief Executive Officer
Chairperson of the Board, Co-Chief Executive Officer
2.44M
+2.60%
Dr. Darya Chudova
Dr. Darya Chudova
Chief Technology Officer
Chief Technology Officer
83.94K
+4.80%
Dr. Craig Eagle, M.D.
Dr. Craig Eagle, M.D.
Chief Medical Officer
Chief Medical Officer
72.00K
+7.81%
Mr. Kumud Kalia
Mr. Kumud Kalia
Chief Information Officer
Chief Information Officer
38.47K
-21.04%
Mr. John Gomes Saia
Mr. John Gomes Saia
Chief Legal Officer, Corporate Secretary
Chief Legal Officer, Corporate Secretary
36.44K
+1.33%
Ms. Vijaya V. Gadde
Ms. Vijaya V. Gadde
Independent Director
Independent Director
28.52K
+14.74%
Ms. Myrtle Stephens Potter
Ms. Myrtle Stephens Potter
Independent Director
Independent Director
20.97K
+12.62%
Ms. Meghan V. Joyce
Ms. Meghan V. Joyce
Independent Director
Independent Director
15.39K
+27.32%
Mr. Musa Tariq
Mr. Musa Tariq
Independent Director
Independent Director
11.05K
+21.60%
Dr. Amirali Talasaz, Ph.D.
Dr. Amirali Talasaz, Ph.D.
Co-Chief Executive Officer, Director
Co-Chief Executive Officer, Director
--
--
Mehr Anzeigen
Name
Name/Position
Position
Aktienbesitz
Veränderung
Dr. Helmy A. Eltoukhy, Ph.D.
Dr. Helmy A. Eltoukhy, Ph.D.
Chairperson of the Board, Co-Chief Executive Officer
Chairperson of the Board, Co-Chief Executive Officer
2.44M
+2.60%
Dr. Darya Chudova
Dr. Darya Chudova
Chief Technology Officer
Chief Technology Officer
83.94K
+4.80%
Dr. Craig Eagle, M.D.
Dr. Craig Eagle, M.D.
Chief Medical Officer
Chief Medical Officer
72.00K
+7.81%
Mr. Kumud Kalia
Mr. Kumud Kalia
Chief Information Officer
Chief Information Officer
38.47K
-21.04%
Mr. John Gomes Saia
Mr. John Gomes Saia
Chief Legal Officer, Corporate Secretary
Chief Legal Officer, Corporate Secretary
36.44K
+1.33%
Ms. Vijaya V. Gadde
Ms. Vijaya V. Gadde
Independent Director
Independent Director
28.52K
+14.74%

Häufig gestellte Fragen

Wer sind die fünf größten Anteilseigner von Guardant Health Inc?

Die fünf größten Anteilseigner von Guardant Health Inc sind: Dr. Helmy A. Eltoukhy, Ph.D.

Wie viele Institutionen halten Anteile an Guardant Health Inc (GH)?

Mit Stand vom 2026Q1 halten 894 Institutionen Anteile an Guardant Health Inc, mit einem Gesamtmarktwert von etwa 134.76M, was 101.63% der Gesamtanteile entspricht. Im Vergleich zum 2025Q4 ist der institutionelle Aktienbesitz um -4828187.00 gestiegen.

Was ist die größte Einnahmequelle von Guardant Health Inc?

Am 2026Q1 erzielte das Geschäft mit Oncology für Guardant Health Inc den höchsten Umsatz in Höhe von 683.60M, was 69.61% des Gesamtumsatzes entspricht.
KeyAI